MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $28.93 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,090,774 shares of the biopharmaceutical company’s stock after buying an additional 82,594 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Pfizer were worth $28,934,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Fiduciary Alliance LLC grew its holdings in shares of Pfizer by 15.5% in the 4th quarter. Fiduciary Alliance LLC now owns 9,803 shares of the biopharmaceutical company’s stock valued at $260,000 after buying an additional 1,319 shares during the period. Rosenberg Matthew Hamilton grew its holdings in shares of Pfizer by 59.9% in the 4th quarter. Rosenberg Matthew Hamilton now owns 2,029 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 760 shares during the period. Mayfair Advisory Group LLC grew its holdings in shares of Pfizer by 4.7% in the 4th quarter. Mayfair Advisory Group LLC now owns 10,758 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 479 shares during the period. 626 Financial LLC grew its holdings in shares of Pfizer by 15.4% in the 4th quarter. 626 Financial LLC now owns 48,849 shares of the biopharmaceutical company’s stock valued at $1,296,000 after buying an additional 6,514 shares during the period. Finally, Accurate Wealth Management LLC grew its holdings in shares of Pfizer by 17.6% in the 4th quarter. Accurate Wealth Management LLC now owns 35,736 shares of the biopharmaceutical company’s stock valued at $955,000 after buying an additional 5,360 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several research analyst reports. Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target for the company. UBS Group boosted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Stock Down 3.8%

NYSE:PFE opened at $22.01 on Thursday. The firm has a market capitalization of $125.13 billion, a price-to-earnings ratio of 15.61, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock’s 50 day moving average price is $23.80 and its two-hundred day moving average price is $25.44. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.82 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.81%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.